Short-term overlap lamivudine treatment with adefovir dipivoxil in patients with lamivudine-resistant chronic hepatitis B

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 14, Issue 11

This Article

Citation of this article

Corresponding Author of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

All Articles published online

Item

Count

PDF

206

HTML

1117

Tables (1-3)

187

Sum=1510

Mar 21, 2008 (publication date) through Nov 4, 2024

Times Cited of This Article

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Rapid Communication

World J Gastroenterol. Mar 21, 2008; 14(11): 1781-1784
Published online Mar 21, 2008. doi: 10.3748/wjg.14.1781

Table 1 Baseline characteristics of patients in each group

	Overlap	Non-overlap
Age (yr)	43.3 ± 8.9	43.7 ± 13.0
Male/female ratio	32/8	29/11
Baseline ALT (IU/L)	188.4 ± 74.1	209.6 ± 130.6
Baseline HBV DNA	6.9 ± 0.6	6.9 ± 0.7
(log₁₀ copy/mL)
Median lamivudine treatment (mo)	21.5	20.3
HBeAg positive/negative	22/18	25/15

Citation: Nam SW, Bae SH, Lee SW, Kim YS, Kang SB, Choi JY, Cho SH, Yoon SK, Han JY, Yang JM, Lee YS. Short-term overlap lamivudine treatment with adefovir dipivoxil in patients with lamivudine-resistant chronic hepatitis B. World J Gastroenterol 2008; 14(11): 1781-1784
URL: https://www.wjgnet.com/1007-9327/full/v14/i11/1781.htm
DOI: https://dx.doi.org/10.3748/wjg.14.1781